BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34859418)

  • 21. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
    Sanz J; Galimard JE; Labopin M; Afanasyev B; Sergeevich MI; Angelucci E; Kröger N; Koc Y; Ciceri F; Diez-Martin JL; Arat M; Sica S; Rovira M; Aljurf M; Tischer J; Savani B; Ruggeri A; Nagler A; Mohty M
    J Hematol Oncol; 2021 May; 14(1):84. PubMed ID: 34049582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
    Canaani J; Savani BN; Labopin M; Huang XJ; Ciceri F; Arcese W; Koc Y; Tischer J; Blaise D; Gülbas Z; Van Lint MT; Bruno B; Mohty M; Nagler A
    Am J Hematol; 2018 Feb; 93(2):246-253. PubMed ID: 29114918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
    Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Arcuri LJ; Aguiar MTM; Ribeiro AAF; Pacheco AGF
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2422-2430. PubMed ID: 31386903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2020; 29():963689720964771. PubMed ID: 33040595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
    Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
    Front Immunol; 2020; 11():191. PubMed ID: 32117310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
    Bashey A; Solomon SR
    Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
    DeZern AE; Franklin C; Tsai HL; Imus PH; Cooke KR; Varadhan R; Jones RJ
    Blood Adv; 2021 Mar; 5(5):1360-1368. PubMed ID: 33661299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?
    Abou-Ismail MY; Fraser R; Allbee-Johnson M; Metheny L; Ravi G; Ahn KW; Bhatt NS; Lazarus HM; de Lima M; El Jurdy N; Hematti P; Beitinjaneh AM; Nishihori T; Badawy SM; Sharma A; Pasquini MC; Savani BN; Sorror ML; Stadtmauer EA; Chhabra S
    Br J Haematol; 2022 May; 197(3):326-338. PubMed ID: 35286719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    Santoro N; Labopin M; Giannotti F; Ehninger G; Niederwieser D; Brecht A; Stelljes M; Kröger N; Einsele H; Eder M; Hallek M; Glass B; Finke J; Ciceri F; Mohty M; Ruggeri A; Nagler A
    J Hematol Oncol; 2018 Apr; 11(1):55. PubMed ID: 29661208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
    McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.